B7-H3 expressing metastatic castration-resistant prostate cancer
AKTSAktis OncologyCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for [225Ac]Ac-AKY-2519 (AKY-2519) in B7-H3 expressing metastatic castration-resistant prostate cancer. The expected timing is based on the latest available company guidance and may change.
BActinium-1 trial. 5/4/26- Ph1b initiated in B7-H3 expressing mCRPC, including PLUVICTO-naïve and -experienced patients; prelim data in 2027. 08/13/26:- First-in-human imaging and dosimetry data were presented at ASCO. BActinium-1 enrollment continued; preliminary data are expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.